Team SAMBAI, including Yemaachi Biotech, named as recipient of prestigious Cancer Grand Challenges award
Team SAMBAI, led by Melissa B. Davis, PhD, of Morehouse School of Medicine, and comprised of collaborators from 14 institutions globally will receive $25M from Cancer Grand Challenges over five years to take on the challenge of cancer inequities
Diversifying precision oncology: Global solutions inspired by Africa
Yemaachi is excited to announce our upcoming webinar, featuring a global panel of experts from academia, industry, venture, and clinical trials.
The webinar will be held on February 28th at 8 AM PT / 11 AM ET / 4 PM GMT.
Yemaachi Furthers African Cancer Research Agenda With New Breast Cancer Mutation, Research Networks
Yemaachi Biotech is preparing to expand a whole-exome sequencing pilot study, while pushing forward several other pan-African cancer research initiatives.
Radiologic patterns of distant organ metastasis in advanced breast cancer patients
Breast cancer (BC) metastases to the abdomen and pelvis affect the liver, mesentery, retroperitoneum, peritoneum, bladder, kidney, ovary, and uterus. The study documented the radiological pattern and features of the chest, bone, abdominal and pelvic (AP) metastases among advanced breast cancer patients.
Yemaachi Presents Findings on Mutation Profiles of Ghanaian Women with Breast Cancer at AORTIC 2023; Announces Formation of African Clinical Cancer Research Network
Results presented in collaboration with Paemka Research Group at the University of Ghana represent largest sequencing study of its kind conducted entirely in Africa to date; Company’s cancer network will advance and scale precision oncology research and collaborations across the continent
BRECXOME – Whole Exome Sequencing of Breast Cancer Tumour Samples from Ghanaian Women
Yemaachi shared findings from a its BreCXome study in an abstract presentation at the 14th AORTIC International Conference on Cancer in Africa
African scientists call for research equity as a cancer crisis looms
At Yemaachi, Bediako is developing cancer diagnostics and treatments tailored to Africans, and he describes the limited official data on patients with cancer across Africa as a major challenge.
Assessing the utility of liquid biopsy for detecting actionable genetic mutations among indigenous Ghanaian women with metastatic breast cancer.
Liquid biopsy detected multiple actionable variants in Ghanaian women with breast cancer that a tissue-only workflow missed. cfDNA analysis featured less variations in sample preparation which is a key consideration in resource-limited settings.
Liquid Biopsy – The necessary first step towards democratising precision oncology?African biotech holds the key to transforming not just the health of African people, but our economies as well
While IHC and imaging are useful for diagnosing and staging cancers, they are limited in their ability to inform clinical decision-making regarding the use of increasingly available targeted therapies that are revolutionising cancer care in developed countries. For this, more advanced molecular tests are required, and next generation sequencing-based liquid biopsy tests are at the cutting edge.